Compare MYE & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYE | APMD |
|---|---|---|
| Founded | 1933 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 895.5M |
| IPO Year | 1995 | 2026 |
| Metric | MYE | APMD |
|---|---|---|
| Price | $26.21 | $16.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 320.1K | ★ 360.0K |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 389.47 | N/A |
| EPS | 0.46 | ★ 9.63 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $158.34 |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | $58.41 | ★ $1.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.11 | $13.88 |
| 52 Week High | $37.45 | $35.29 |
| Indicator | MYE | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.08 | 47.97 |
| Support Level | $26.72 | $16.43 |
| Resistance Level | $32.10 | $19.83 |
| Average True Range (ATR) | 1.12 | 1.48 |
| MACD | -0.12 | 0.41 |
| Stochastic Oscillator | 11.87 | 64.67 |
Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).